Common Contracts

1 similar Development and Manufacturing Agreement contracts

Anthos Therapeutics Partners with Lonza to Develop and Manufacture Abelacimab (MAA868), a Unique Dual Factor XI / XIa inhibitor
Development and Manufacturing Agreement • June 10th, 2020

 The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.